

Terry G J Derks

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5869438/terry-g-j-derks-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69

papers

968

citations

19

h-index

27

g-index

78

ext. papers

1,237

ext. citations

5.4

avg, IF

4.2

L-index

#	Paper	IF	Citations
69	Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. <i>Journal of Inherited Metabolic Disease</i> , 2016 , 39, 697-704	5.4	83
68	The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: clinical presentation and outcome. <i>Journal of Pediatrics</i> , 2006 , 148, 665-670	3.6	77
67	Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. <i>Blood</i> , 2020 , 136, 1033-1043	2.2	39
66	Inborn Errors of Metabolism with Hypoglycemia: Glycogen Storage Diseases and Inherited Disorders of Gluconeogenesis. <i>Pediatric Clinics of North America</i> , 2018 , 65, 247-265	3.6	36
65	Evaluation of glycogen storage disease as a cause of ketotic hypoglycemia in children. <i>Journal of Inherited Metabolic Disease</i> , 2015 , 38, 489-93	5.4	34
64	Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions. <i>Journal of Inherited Metabolic Disease</i> , 2015 , 38, 537-43	5.4	34
63	Disturbed hepatic carbohydrate management during high metabolic demand in medium-chain acyl-CoA dehydrogenase (MCAD)-deficient mice. <i>Hepatology</i> , 2008 , 47, 1894-904	11.2	34
62	Dietary management in glycogen storage disease type III: what is the evidence?. <i>Journal of Inherited Metabolic Disease</i> , 2015 , 38, 545-50	5.4	30
61	Safe and unsafe duration of fasting for children with MCAD deficiency. <i>European Journal of Pediatrics</i> , 2007 , 166, 5-11	4.1	29
60	Inhibition of mitochondrial fatty acid oxidation in vivo only slightly suppresses gluconeogenesis but enhances clearance of glucose in mice. <i>Hepatology</i> , 2008 , 47, 1032-42	11.2	26
59	The difference between observed and expected prevalence of MCAD deficiency in The Netherlands: a genetic epidemiological study. <i>European Journal of Human Genetics</i> , 2005 , 13, 947-52	5.3	26
58	Inborn Errors of Metabolism That Cause Sudden Infant Death: A Systematic Review with Implications for Population Neonatal Screening Programmes. <i>Neonatology</i> , 2016 , 109, 297-302	4	25
57	Pathogenic variants in glutamyl-tRNA amidotransferase subunits cause a lethal mitochondrial cardiomyopathy disorder. <i>Nature Communications</i> , 2018 , 9, 4065	17.4	24
56	Dietary treatment of glycogen storage disease type Ia: uncooked cornstarch and/or continuous nocturnal gastric drip-feeding?. <i>Molecular Genetics and Metabolism</i> , 2013 , 109, 1-2	3.7	23
55	Nine years of newborn screening for classical galactosemia in the Netherlands: Effectiveness of screening methods, and identification of patients with previously unreported phenotypes. <i>Molecular Genetics and Metabolism</i> , 2017 , 120, 223-228	3.7	21
54	Risk stratification by residual enzyme activity after newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: data from a cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2012 , 7, 30	4.2	20
53	Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands. <i>Journal of Pediatrics</i> , 2007 , 151, 115-20, 120.e1-3	3.6	19

52	Movement disorders and nonmotor neuropsychological symptoms in children and adults with classical galactosemia. <i>Journal of Inherited Metabolic Disease</i> , 2019 , 42, 451-458	5.4	19
51	Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes. <i>Journal of Inherited Metabolic Disease</i> , 2019 , 42, 414-423	5.4	19
50	Research priorities for liver glycogen storage disease: An international priority setting partnership with the James Lind Alliance. <i>Journal of Inherited Metabolic Disease</i> , 2020 , 43, 279-289	5.4	19
49	Proposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency. <i>Journal of Inherited Metabolic Disease</i> , 2019 , 42, 159-168	5.4	18
48	Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD. <i>Pediatrics</i> , 2014 , 134, e1224-8	7.4	17
47	Experimental evidence for protein oxidative damage and altered antioxidant defense in patients with medium-chain acyl-CoA dehydrogenase deficiency. <i>Journal of Inherited Metabolic Disease</i> , 2014 , 37, 783-9	5.4	16
46	Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control. <i>Journal of Inherited Metabolic Disease</i> , 2017 , 40, 695-702	5.4	15
45	Living on the edge: substrate competition explains loss of robustness in mitochondrial fatty-acid oxidation disorders. <i>BMC Biology</i> , 2016 , 14, 107	7.3	15
44	Biallelic variants in WARS2 encoding mitochondrial tryptophanyl-tRNA synthase in six individuals with mitochondrial encephalopathy. <i>Human Mutation</i> , 2017 , 38, 1786-1795	4.7	15
43	In vitro digestion of starches in a dynamic gastrointestinal model: an innovative study to optimize dietary management of patients with hepatic glycogen storage diseases. <i>Journal of Inherited Metabolic Disease</i> , 2015 , 38, 529-36	5.4	14
42	Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiency. <i>Genetics in Medicine</i> , 2020 , 22, 908-916	8.1	13
41	A nationwide retrospective observational study of population newborn screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in the Netherlands. <i>Journal of Inherited Metabolic Disease</i> , 2019 , 42, 890-897	5.4	12
40	Normoglycemic Ketonemia as Biochemical Presentation in Ketotic Glycogen Storage Disease. <i>JIMD Reports</i> , 2016 , 28, 41-47	1.9	12
39	Dietary lipids in glycogen storage disease type III: A systematic literature study, case studies, and future recommendations. <i>Journal of Inherited Metabolic Disease</i> , 2020 , 43, 770-777	5.4	12
38	Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia. <i>Hepatology</i> , 2017 , 66, 2042-2054	11.2	12
37	Determination of amylose/amylopectin ratio of starches. <i>Journal of Inherited Metabolic Disease</i> , 2015 , 38, 985-6	5.4	11
36	Muscle Ultrasound in Patients with Glycogen Storage Disease Types I and III. <i>Ultrasound in Medicine and Biology</i> , 2016 , 42, 133-42	3.5	11
35	Inflammatory Bowel Disease in Glycogen Storage Disease Type Ia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017 , 64, e52-e54	2.8	10

34	Safety issues associated with dietary management in patients with hepatic glycogen storage disease. <i>Molecular Genetics and Metabolism</i> , 2018 , 125, 79-85	3.7	10
33	Prediction of disease severity in multiple acyl-CoA dehydrogenase deficiency: A retrospective and laboratory cohort study. <i>Journal of Inherited Metabolic Disease</i> , 2019 , 42, 878-889	5.4	10
32	Recombinant phenylalanine ammonia lyase in phenylketonuria. <i>Lancet, The</i> , 2014 , 384, 6-8	4.0	10
31	Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 218	4.2	10
30	Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia. <i>Journal of Inherited Metabolic Disease</i> , 2021 , 44, 879-892	5.4	7
29	What Is the Best Blood Sampling Time for Metabolic Control of Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients?. <i>JIMD Reports</i> , 2017 , 36, 49-57	1.9	6
28	A preliminary study of telemedicine for patients with hepatic glycogen storage disease and their healthcare providers: from bedside to home site monitoring. <i>Journal of Inherited Metabolic Disease</i> , 2018 , 41, 929-936	5.4	6
27	Complex patterns of inheritance, including synergistic heterozygosity, in inborn errors of metabolism: Implications for precision medicine driven diagnosis and treatment. <i>Molecular Genetics and Metabolism</i> , 2019 , 128, 1-9	3.7	6
26	Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report. <i>Italian Journal of Pediatrics</i> , 2021 , 47, 149	3.2	6
25	Glycogen storage disease type Ia: Adult presentation with microcytic anemia and liver adenomas. <i>Hepatology</i> , 2018 , 68, 780-782	11.2	5
24	Acute exercise in treated phenylketonuria patients: Physical activity and biochemical response. <i>Molecular Genetics and Metabolism Reports</i> , 2015 , 5, 55-59	1.8	5
23	The multiple faces of urinary glucose tetrasaccharide as biomarker for patients with hepatic glycogen storage diseases. <i>Genetics in Medicine</i> , 2020 , 22, 1915-1916	8.1	5
22	The potential of dietary treatment in patients with glycogen storage disease type IV. <i>Journal of Inherited Metabolic Disease</i> , 2021 , 44, 693-704	5.4	4
21	Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels. <i>Human Molecular Genetics</i> , 2020 , 29, 264-273	5.6	4
20	A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: A retrospective, single-center study and the generation of www.emergencyprotocol.net. <i>Journal of Inherited Metabolic Disease</i> , 2021 , 44, 1124-1135	5.4	4
19	Changes in pediatric plasma acylcarnitines upon fasting for refined interpretation of metabolic stress. <i>Molecular Genetics and Metabolism</i> , 2019 , 127, 327-335	3.7	3
18	Hepatic Glycogen Storage Diseases: Toward One Global Collaborative Network. <i>FIRE Forum for International Research in Education</i> , 2017 , 5, 232640981773300	1.4	3
17	A retrospective in-depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management. <i>Journal of Inherited Metabolic Disease</i> , 2021 , 44, 1136-1150	5.4	3

16	Effects of acute nutritional ketosis during exercise in adults with glycogen storage disease type IIIa are phenotype-specific: An investigator-initiated, randomized, crossover study. <i>Journal of Inherited Metabolic Disease</i> , 2021 , 44, 226-239	5.4	3
15	Enantiomer-specific pharmacokinetics of D,L-3-hydroxybutyrate: Implications for the treatment of multiple acyl-CoA dehydrogenase deficiency. <i>Journal of Inherited Metabolic Disease</i> , 2021 , 44, 926-938	5.4	3
14	Neonates at risk of medium-chain acyl-CoA dehydrogenase deficiency: a perinatal protocol for use before population neonatal screening test results become available. <i>Genetics in Medicine</i> , 2016 , 18, 1322-1323	8.1	2
13	Transcriptome analysis suggests a compensatory role of the cofactors coenzyme A and NAD in medium-chain acyl-CoA dehydrogenase knockout mice. <i>Scientific Reports</i> , 2019 , 9, 14539	4.9	2
12	Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs. <i>Nutrients</i> , 2021 , 13,	6.7	2
11	Proposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency 2019 , 42, 159		2
10	A triple-blinded crossover study to evaluate the short-term safety of sweet manioc starch for the treatment of glycogen storage disease type Ia. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 254	4.2	2
9	Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire.. <i>Genetics in Medicine</i> , 2022 ,	8.1	2
8	Instability of Acylcarnitines in Stored Dried Blood Spots: The Impact on Retrospective Analysis of Biomarkers for Inborn Errors of Metabolism. <i>International Journal of Neonatal Screening</i> , 2020 , 6,	2.6	1
7	A retrospective study of eating and psychosocial problems in patients with hepatic glycogen storage diseases and idiopathic ketotic hypoglycemia: Towards a standard set of patient-reported outcome measures.. <i>JIMD Reports</i> , 2022 , 63, 29-40	1.9	1
6	Orthotopic Liver Transplantation in Glycogen Storage Disease Type 1a: Perioperative Glucose and Lactate Homeostasis. <i>FIRE Forum for International Research in Education</i> , 2016 , 4, 232640981664959	1.4	1
5	Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing. <i>Hepatology</i> , 2021 , 74, 2491-2507	11.2	0
4	Neonatal Long-Chain 3-Ketoacyl-CoA Thiolase deficiency: Clinical-biochemical phenotype, sodium-D,L-3-hydroxybutyrate treatment experience and cardiac evaluation using speckle echocardiography. <i>Molecular Genetics and Metabolism Reports</i> , 2022 , 31, 100873	1.8	0
3	High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia. <i>JHEP Reports</i> , 2022 , 100512	10.3	0
2	Glycogen Storage Liver Diseases 2020 , 749-754		
1	Disorders of Carbohydrate Absorption, Transmembrane Transport and Metabolism 2022 , 649-700		